09 September 2024 | Monday | News
Picture courtesy | Public Domain
PolTREG S.A. , a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces data showing that treatment with its Treg cell therapy, PTG-007, resulted in clinical remission for up to 12 years in patients with type-1 diabetes (T1D). A subset of these patients remained insulin-independent up to 18 to 24 months after treatment.
“People with type-1 diabetes understand the life-long commitment needed for their care. This is why the results of treating patients over such a long period with our cellular therapy PTG-007 is so important. Today’s results are extremely encouraging, and show that some patients remain in clinical remission for up to 12 years after initial treatment. This makes us very eager to launch a pivotal study of PTG-007 as soon as we find a suitable partner. We believe that PTG-007 has the potential to free many type-1 diabetics from the life-long burden of having to take frequent insulin injections, and the serious long-term complications of the disease,” said Prof Piotr Trzonkowski, Chief Executive Officer of PolTREG.
The clinical study monitored 54 patients who had taken part in Phase I and Phase II trials with PTG-007 to treat early-onset T1D, over a period between 7 and 12 years.
The main findings were:
The company is working to publish the study in a peer-reviewed scientific publication, at which stage it will provide full data disclosure. The long-term safety and efficacy results of its Treg therapy in T1D presented today are a significant competitive advantage and pave the way for the company to launch a pivotal Phase 2/3 study of PTG-007 to treat T1D, for which it is currently seeking partnership funding.
PolTREG holds one of the largest and most advanced pipelines for Treg therapies for autoimmune disease, developing both polyclonal and engineered therapies. Its lead candidate, PTG-007, an autologous polyclonal Treg treatment, is in mid-stage clinical studies for T1D and multiple sclerosis (MS). Later this year, PolTREG will launch a Phase 2 study in presymptomatic T1D patients. Next year, PolTREG expects to start a first-in-human trial of its engineered CAR-Treg, using the PTG-007 platform, for treatment of MS and amyotrophic lateral sclerosis (ALS). The company also is in preclinical development with two further types of engineered Treg cells.
© 2025 Biopharma Boardroom. All Rights Reserved.